Article Sidebar
Published:
Feb 16, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of immunotherapy on T lymphocyte subsets, FOXP3 and IFN-γ/IL-4 ratio in children with allergic asthma
Abstract
Purpose: To study the effect of specific immunotherapy on T lymphocyte subsets, FOXP3 and IFN-γ/IL-4 in children with allergic asthma (AA).
Methods: 57 AA children were selected and received the allergen specific immunotherapy, thereafter, the T lymphocyte subsets, FOXP3 and IFN-γ/IL-4 ratio were measured at three time points, before treatment, after 1yr and 2yr of treatment. Then the clinical efficacy after 2yr was recorded.
Results: The pre- and post- treatment percentages of CD4 + CD25 + T cells in CD4 + T cells had no difference (P>0.05). The proportion of CD4 + CD25 high T cells in CD4 + T was significantly increased after 1yr and 2yr of treatment (P<0.05), the difference between that after 1yr and 2yr of treatment was not significant. The relative expression of FOXP3 at three time points in a descending order was after 1yr, 2yr of treatment and pre-treatment (P<0.05). The relative IFN-γ expression after 1yr of treatment increased and returned to pre-treatment level after 2yr of treatment; IL-4 expression levels decreased as the treatment time extended; The IFN-γ/IL-4 ratio at three time points in a descending order was after 1yr, 2yr of treatment and pretreatment (P<0.05). The levels of IL-4 and IFN-γ in the children increased significantly as treatment time extended (P<0.05), and became stable after 1yr and 2yr of treatment, while the concentration of IL-4 showed a decrease trend (P<0.05), also tended to be stable after 1yr and 2yr of treatment. The clinical efficacy after 2yr of treatment was 87.72%.
Conclusion: This study has revealed that FOXP3, IFN-γ, and IL-4 have significant roles FOXP3 in the process of specific immunotherapy for children with allergic asthma. Further studies are needed to explore the mechanism.
